The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.

Also called NCT03599284

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 279 participants (enrolled count) (from the registry)
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD (from the registry)
Registry
  • NCT NCT03599284
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03599284. Randomized; quadruple masking; primary purpose treatment. Start 2018-08-30 (actual); primary completion 2019-06-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
Condition
Platelet Aggregation Inhibitors
Intervention (Drug)
Vicagrel 5mg
Intervention (Drug)
Vicagrel 6mg
Intervention (Drug)
Vicagrel 7.5mg
Intervention (Drug)
Clopidogrel 75mg
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD (class: industry)

Record details

Record id
cardio:ct-nct03599284
Content hash
3ebd7f49b7cb5a031e4c45d58661f02e55bfe25acd2d23e533db5a33bcfc2717